1	Wei Ren Anti-Wart Formula combined with photodynamic						
2	therapy for Condyloma acuminate: a double-blind, randomized,						
3	parallel-group trial						
4	ShiYan Yang <sup>1</sup> <sup>§</sup> , Liang Hua <sup>1</sup> <sup>§</sup> , Dongjie Guo <sup>1</sup> , Yifei Wang <sup>1</sup> , Xuqiang Wei <sup>2*</sup> , Fulun Li <sup>1*</sup>						
5	<sup>1</sup> Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and						
6	Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai,						
7	China, 200437						
8	<sup>2</sup> Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated						
9	Traditional Chinese and Western Medicine, Shanghai University of Traditional						
10	Chinese Medicine, Shanghai, China, 200437						
11	Author contact information						
12	Shi-Yan Yang: ysya2022@163.com Liang Hua: 18916017563 @163.com						
13	Correspondence to Xuqiang Wei: wxqzdyx123@163.com						
14	Phone number: 18916026080						
15	Correspondence to Dr Fulun Li: drlifulun@163.com						
16	Phone number: 18918757260						
17	* Correspondence: Xuqiang Wei, Fulun Li						
18	§ These authors equally contributed to this work.						
19	Word count (excluding title page, abstract, references, figures, and tables): 4151						
20							

2

#### 21 ABSTRACT

Introduction: Condyloma acuminate (CA) is a chronic disease with a high rate of 22 23 recurrence which has a detrimental impact on patients' physical and mental health, as well as their quality of life and socioeconomic advancement. Photodynamic therapy 24 is a less invasive and selective intervention for CA, but its safety and high price limit 25 its utilization. Wei Ren Anti-Wart Formula (WRAWF), is a promising Chinese 26 medicine for CA, however, the evidence of its effectiveness and safety is scarcely. 27 This trial aimed to evaluate the clinical effectiveness, safety, and recurrence 28 29 management of WRAWF combined with photodynamic in the CA patients.

30

Methods and analysis: A double-blind, randomized, parallel-group trial was 31 32 designed. Participants will recruit in the Yue Yang Traditional Chinese Medicine Hospital, Shanghai University of Traditional Chinese Medicine from May 1, 2024, to 33 December 31, 2025. The sample size is 148 CA patients (74 in each group), will 34 randomly divide into the trial and control groups. followed up at weeks 6, 10, and 14 35 after the 2-week treatment period. The recurrence rate will be set as the primary 36 outcome. The visual analogue scale (VAS) scores of pain, the rate of infection, 37 superficial scarring, and the type, severity, and incidence of adverse events will be 38 carefully documented at 0,1,2,6,10,14 weeks. 39

40

41 Ethics and dissemination: This trial has approved by the Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated 42

reserved. No reuse allowed without permissio
--

43	to Shanghai University of Traditional Chinese Medicine (No. 2023-023). Meanwhile,						
44	informed consent was provided by all patients conducted in accordance with the						
45	Declaration of Helsinki.						
46							
47	Trial registration number: ChiCTR2300071609; www.chictr.org.cn;Registered on						
48	April19, 2023(first version).						
49							
50	Key words: Randomized trial, Condyloma acuminate, photodynamic therapy, Wei						
51	Ren Anti-Wart Formula						
52							
53	Strengths and limitations of this study						
53 54	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence						
53 54 55	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the						
53 54 55 56	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for						
53 54 55 56 57	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for the formation of a standardized treatment plan.						
53 54 55 56 57 58	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for the formation of a standardized treatment plan. Photodynamic therapy and Chinese medicine for the treatment of CA each have their						
53 54 55 56 57 58 59	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for the formation of a standardized treatment plan. Photodynamic therapy and Chinese medicine for the treatment of CA each have their characteristics and complementary advantages. To improve the success rate of the						
53 54 55 56 57 58 59 60	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for the formation of a standardized treatment plan. Photodynamic therapy and Chinese medicine for the treatment of CA each have their characteristics and complementary advantages. To improve the success rate of the patient's CA treatment and at the same time reduce to some extent the shortcomings of						
53 54 55 56 57 58 59 60 61	Strengths and limitations of this study This study evaluate the clinical efficacy, safety, and control of disease recurrence of CA by sequential treatment of Chinese and Western medicine, to clarify the advantages of Chinese medicine in the treatment of CA, and for providing a basis for the formation of a standardized treatment plan. Photodynamic therapy and Chinese medicine for the treatment of CA each have their characteristics and complementary advantages. To improve the success rate of the patient's CA treatment and at the same time reduce to some extent the shortcomings of photodynamic therapy alone such as side effects and easy recurrence.						

4

#### BACKGROUND 63

Condyloma acuminate (CA), also known as anogenital warts, is a sexually 64 65 transmitted disease caused by human papillomavirus (HPV) infection that is primarily a warty, proliferative lesion of the skin and mucous membranes. It typically affects the 66 skin and mucous membranes of the vaginal, anal, and perianal areas, and yet it can 67 also affect the inguinal and perineal areas. It has a very high recurrence rate, with a 68 large sample showing a recurrence rate of (47-163)/100,000 in mele and 69 (23-110)/100,000 in female.[1–4] As a result, CA is prone to recurrence, with the 70 71 maximum recurrence rate occurring within 3 months, and then progressively declining as time goes on. Therefore, it requires long-term, frequent treatment. 72 73 Additionally, there is a significant influence on the patient's everyday life and mental 74 health.

Photodynamic therapy (PDT) is a topical application of the photosensitizer 75 5-aminoketovaleric acid (ALA), followed by topical light treatment with a 76 77 semiconductor laser or light emitting diode (LED), usually using red light (630-635 nm). It is indicated for the removal of smaller warts and basal treatment after physical 78 therapy has removed larger warts. The treatment was performed with a 10%-20% 79 solution of 5-ALA applied to the lesion, extending to 1 cm around the wart, covering 80 81 the subclinical area of infection around the wart as much as possible. For external genital warts, 3-4 sessions are recommended as a course of treatment for initial cases 82 83 and 4-6 sessions for recurrent and recalcitrant cases.[5] The advantage is that it is non-destructive compared to other therapies such as laser and freezing, can be 84

5

repeated, and is less likely to cause tissue defects and dysfunction. However, its high 85 treatment price limits its clinical application. 86

87 Wei Ren Anti-Wart Formula (WRAWF), a Chinese herbal prescription, is a compound preparation with eight ingredients (Clematis chinensis Osbeck, Coicis Semen, Salvia 88 miltiorrhiza Bunge, Astragali Radix, Atractylodes macrocephala Koidz, Hedyotidis 89 Herba, Portulaca and Curcumae Rhizoma), achieving clinical efficacy in the external 90 treatment of CA. It has the advantages of simple use, low treatment cost and few side 91 effects. External use can act on the wart body. 92

93 Modern studies have shown that all the extracts of clematichinenoside have significant anti-inflammatory, analgesic, antispasmodic and effects.[6] 94 The 95 triglyceride component of Coix lacryma has anti-tumor effects, and its analgesic and 96 anti-inflammatory effects have also been confirmed.[7,8] The mechanism of action of Salvia miltiorrhiza may be to suppress the inflammatory response of endothelial cells 97 by down-regulating the expression of CD40 signals.[9] Astragalus polysaccharides 98 99 have protective effects against oxidative stress injury and immune damage, and they promote immune function in traumatic tissues and facilitate wound repair.[10-12] 100 Curcumin, the main component of Curcuma longa, has antitumor and antioxidant 101 effects, and its ability to effectively scavenge free radicals leads to a reduction in the 102 possibility of cellular carcinogenesis, and its mechanism of action meets the 103 requirements of modern medicine needed for anti-photodamage drugs.[13] Therefore, 104 105 the combination of the above-mentioned herbs and photodynamic therapy can not only play a role in reducing the recurrence rate of CA but also synergistically reduce 106

6

the side effects of treatment and improve the regional immune function with 107 photodynamic therapy. 108

109 Therefore, this trial adopts a A double-blind, randomized, parallel-group design to This trial evaluate the clinical effectiveness, safety, and recurrence management of the 110 WRAWF combined with photodynamic in the CA patients objectively. The result 111 will obtain high-level evidence-based medical evidence of Chinese medicine in the 112 treatment of CA. This protocol will be reported in line with the SPIRIT checklist. 113

#### **METHODS** 114

#### Design 115

This is a double-blind, randomized, parallel-group clinical trial. The aim is to 116 elucidate the clinical efficacy, safety, and recurrence of WRAWF combined with 117 118 photodynamic therapy. The results of the study will establish the clinical standard for sequential treatment of CA with Chinese and Western medicine. The trial protocol 119 (version 1.0, July 3, 2022) is being written and enrollment in the trial has not yet 120 121 begun. Recruitment is expected to begin on May 1, 2024, and end on December 31, 122 2025.

Participants will recruit from the outpatients of Yueyang Hospital of Integrative 123 Medicine, affiliated with Shanghai University of Traditional Chinese Medicine. A 124 total of 148 patients will be enrolled in this clinical trial. 125

five The study consists of screening/enrollment, allocation, 126 phases: 127 treatment/intervention, end of intervention, and follow-up. In the enrollment process, participants will be recruited via a Condyloma acuminate clinic for physical 128

7

examination and eligibility assessment. The time between the assessment and the 129 intervention should not be longer than one week (week 0). If more than a week has 130 131 passed since the assessment, assessment of the participant will be repeated before the intervention. If eligible, the participants will be requested to sign the written informed 132 consent regarding participation in the trial (procedures, risks, options for dropping 133 out), the use of laboratory data, and collection, storage, and use of biological 134 specimens. Details of the informed consent will be explained by study investigators or 135 medical staff members with adequate training. Once informed consent form is signed 136 137 and dated by the participant, a participant identification (PID) number will be assigned to facilitate participant identification of the study. 138

For the random distribution of WRAWF groups and placebo group, randomisation 139 140 will be performed by drawing lots, using the research randomiser program (https://www.randomizer.org/). The allocation sequence will be made by a different 141 researcher, who will not be involved in the procedures. 142

143 The participants will be randomly allocated to the WRAWF group or placebo group. PIDs will be grouped by research randomiser program (https://www.randomizer.org/). 144 We will treat the participants in the WRAWF group with WRAWF and PDT, those in 145 the placebo group with WRAWF placebo and PDT (Fig 1). The participants will 146 receive systemic therapy as per the judgment of their treating physicians. We will 147 record all changes in symptoms, prescriptions, relevant scores, and macroscopic 148 characteristics (based on photographic evidence), as well as any adverse events. 149

The trial protocol was approved by the Ethics Committee of Shanghai Yueyang 150

8

Hospital of Integrative Medicine and registered in the Clinical Trials Registry. 151

- Registration number: 2023-023 152
- **Eligibility criteria** 153
- Inclusion criteria 154
- clinical diagnosis of CA, between 18 and 65 years of age; both sexes. 155 a)
- warts located in the perianal area, distal urethra, and external genitalia. 156 b)
- who voluntarily participated in this study and signed the informed consent form. 157 c)
- Exclusion criteria 158
- 159 a) Those who have undergone ALA-PDT treatment within 12 weeks and those who
- apply any other treatment that affects the study. 160
- Those with a combination of other conditions that may affect the evaluation of 161 b)
- 162 efficacy, such as other photo dermatological conditions, combination of severe
- localized infections. 163
- those who have taken phototoxic or photosensitizing drugs within 12 weeks 164 c)
- 165 d) clinical and/or pathological evidence of tumor invasion to other organs or tissues.
- Severely immunocompromised individuals. 166 e)
- f) Scarred individuals. 167
- Those with known cutaneous photosensitivity, porphyria, or allergy to ALA, light, 168 **g**) or lidocaine 169
- Those with severe medical, psychological, and psychiatric illnesses, infectious 170 h) 171 diseases, or pregnant or lactating women.
- Any other reason deemed by the investigator to be inappropriate for participation 172 i)

9

in this study. 173

**Intervention:** 174

#### **Trial group intervention:** 175

On day 0, day 7, and day 14 of the trial, we gave WRAWF topical application + 176 177 Aminoglutaric Acid Hydrochloride topical dispersion + He-Ne laser irradiation once respectively. 178

Specifically: the test group will get 1 packet of WRAWF granules per dose, put all the 179 granules of each packet into the same container, pour in about 5 ml of water for 180 181 injection, stir until the granules are dissolved, and apply them externally for 30 minutes. Later Aminoketovaleric Acid Hydrochloride topical application is dissolved 182 in water for injection before use (118mg/bottle add 0.5ml), prepared into a solution 183 184 with a concentration of 20%. After cleaning the affected area and keeping it dry, put the 20% solution of amino glutarate hydrochloride on the cotton ball and cover the 185 surface of the wart, repeat the solution on the cotton ball every 30 minutes or so, and 186 187 keep dressing on the affected area for not less than 3 hours. The entire procedure should be done in a light-proof environment, and the affected area should be protected 188 from direct light after the application of the medication. Subsequently, a helium-neon 189 laser is used, with an output wavelength of 632.8 nm and laser energy of 100-150 190 J/cm, and the treatment spot completely covers the lesion. 191

**Control group intervention:** 192

193 Placebo topical application + Aminoketovaleric acid hydrochloride topical dispersion + He-Ne laser irradiation 194

10

Specifically: Using placebo topical, placebo herbal granules were composed of a 195 matrix, color correcting agent, flavoring agent, and a solvent selected according to the 196 ingredient ratio, made by mixing, drying, crushing, sieving, granulation, and whole 197 granules; the appearance, odor, and color were the same as the test drug. The 198 remaining treatment method was the same as the test group. 199

**Outcome measures** 200

By employing deterministic, A double-blind, randomized, parallel-group trial, we 201 aim to furnish precise directives for the secure management of patients diagnosed 202 203 with Condyloma acuminate. Data derived from the envisaged outcome metrics will be amassed for subsequent investigations encompassing larger cohorts. Parameters such 204 as recruitment and retention rates, the percentage of patients failing to meet eligibility 205 206 criteria, and patients' inclination towards random assignment will be computed. Additionally, assessments will be conducted on compliance levels, qualitative 207 feedback, and compliance rates. Economical data pertaining to the utilization of 208 209 medical resources and health-related quality of life will be gathered and subjected to comprehensive analysis. Safety outcome measures will be presented in compliance 210 with the stipulations outlined for a clinical trial designed to scrutinize a 211 pharmaceutical regimen. 212

**Primary outcome:** 213

The main effect indicator was the time to recurrence: the date when a new wart 214 215 was found at the treatment site from the first treatment.

Secondary outcome: 216

11

217	The secondary effect index is the efficacy evaluation criteria - (1) cured: all warts
218	were cleared after treatment and no new warts appeared; (2) significantly effective:
219	the lesion area was reduced by $\ge 90\%$ after treatment; (3) effective: the lesion area
220	was reduced by 60% to 89% after treatment; (4) ineffective: the above criteria were
221	not met. Total effective rate = (cured + effective + effective) / total number of cases $\times$
222	100%. The incidence of pain visual analogue scale (VAS) score, infection, and
223	superficial scar was also recorded during the treatment period, and the patients were
224	scored for pain, infection, and scar. VAS was used for pain assessment; the Vancouver
225	Scar Scale (VVS) was used to count and score the incidence and nature of scarring at
226	the treatment site that appeared late after the patients underwent treatment.(Table 1,
227	2) At the same time, the type, degree, and incidence of adverse events will be
228	recorded.
229	The main adverse eactions include local pruritus, redness, swelling, and pain after
230	treatment; a small number of patients can develop pain at the treatment site at the end
231	of treatment; clinical treatment adverse reactions are classified into the following four
232	levels, as shown in Table 3. In the event of an adverse reaction that is not tolerated by
233	the patient, the follow-up physician can be contacted at any time to ask whether the
234	drug needs to be discontinued or treated for the adverse reaction. The specific

implementation of such measures is reflected in Table 4. 235

Sample size 236

According to the literature, [14] the literature recurrence rate is 26.25%. 237 According to the following formula, we assume that the recurrence rate in the 238

12

combined treatment group is 8.7%, taking  $\alpha$ =0.05 level and test efficacy of 0.8, then 239  $1-\beta=1-0.2=0.8$ , two-sided test, using two sample rates to compare the sample content 240 241 estimation formula. The rate for the test group was  $p_1$  and the rate for the control group was  $p_2$ , yielding a sample content of 70 cases per group, assuming a 5% loss of 242 243 patient follow-up; a total of 148 patients needed to be observed, 74 cases per group.

$$n_1 = n_2 = \frac{p_1 \times (1 - p_1) + p_2(1 - p_2)}{(p_2 - p_1)^2} \times (u\alpha_{/2} + u_\beta)^2$$

#### **Randomization and allocation** 244

The trial was completely randomized and was conducted by the Data 245 246 Management Center of Jiangsu Famaxon Medical Technology Co. The system will give a subject identification number, i.e., subject ID, as a unique identification number 247 after enrollment. After obtaining the subject ID, the subjects were grouped by logging 248 249 into the randomization center website, and the corresponding randomization number was obtained to enter the group. 250

#### **Treatment cycles** 251

252 The study period was 15 weeks in total: photodynamic therapy (3 weeks) + 253 follow-up period (12 weeks).

## Test drugs and blinding 254

The study drug and its placebo were manufactured, packaged, and provided by 255 Sichuan Neo-green Pharmaceutical Technology Development Co., Ltd. The study 256 drug randomization code was the unique identification code for the subjects. A 257 double-blind design was used, and the randomization code table was created by the 258 research randomiser program (https://www.randomizer.org/). Each participant's 259

13

corresponding PID will be given a unique random number and a corresponding drug 260 packet or placebo packet with the same appearance, odor, and color. The project team 261 262 will designate separate dispensers who will not be involved in other parts of that clinical trial. The monitors and outcome evaluators had to be blinded from the 263 beginning to the end. 264

Unblinding regulations: This study provides for one unblinding. The unblinding is 265 done after the blinded verification data is locked, and the staff member who keeps the 266 blinded base will give it to the statistician for statistical analysis. 267

268 Emergency unblinding: When a serious adverse event occurs, or when a patient needs to be resuscitated and other circumstances necessitate knowledge of the drug used by 269 270 the patient, the person in charge of the central trial will decide to unblind the patient 271 in an emergency and open the corresponding emergency letter. Once the emergency letter with the corresponding number is opened, the case will be treated as a dislodged 272 273 case.

#### 274 **Drug combination**

Any medications taken at study entry and during the three months prior to study, 275 entry must be recorded on the Case Report Form (CRF). All medications used during 276 the study are considered to be combined medications and must also be recorded on the 277 CRF form. In particular, all permitted or unpermitted use of any measures for the 278 treatment of psoriasis should be recorded. Combination medications should be 279 280 recorded by type (trade name), dosage, indication, and duration of administration on the appropriate CRF page. The investigator decides whether the patient withdraws 281

14

from the study. 282

I. Permissible combined treatments: certain drugs/other treatments that must be 283 284 taken by patients with comorbid diseases or new comorbid diseases during treatment will be permissible, provided that the name of the drug (or other treatment names), 285 dosage, number and duration of use, etc., are recorded in the study medical record for 286 analysis and reporting at the time of summary. 287

II. Prohibited combined treatments: other internal medications, topical preparations, 288 physiotherapy, etc. to treat the disease, including vitamin D3 derivatives, other herbal 289 290 preparations, etc.

#### **Statistical analysis** 291

Data management was performed using the data management platform designed 292 293 by the Data Management Center of Jiangsu Famaxon Medical Technology Co., Ltd, which included data management, blinded audit, and data export were performed in 294 this platform for data entry. The analyses will be performed using SAS statistical 295 296 software and will include the actual number of subjects enrolled in both groups, disenrollment and exclusion cases, demographic and other baseline characteristics, 297 adherence, efficacy analysis, and safety analysis. 298

Statistical analysis was performed using descriptive statistical analysis and 299 comparative analysis between the two groups. Qualitative indicators were described 300 by frequency tables, percentages, or composition ratios; quantitative indicators were 301 described by means, standard deviations, or medians, lower quartiles (Q1), upper 302 quartiles (Q3), minimums, and maximums. Qualitative data were tested by the 303

15

chi-square test, Fisher's exact probability method, Wilcoxon rank sum test, and CMH 304 test. Quantitative data conformed to a normal distribution by t-test (chi-square test 305 306 between groups, with 0.05 as the test level, and Satterthwaite's method was used for corrected t-test when the variance was not equal), and Wilcoxon rank sum test and 307 Wilcoxon signed rank sum test were used for non-normal distribution. Hypothesis 308 testing was uniformly performed using a two-sided test, giving the test statistic and its 309 corresponding P value, with  $P \le 0.05$  as statistically significant and  $P \le 0.01$  as highly 310 statistically significant. 311

#### **Adverse events** 312

I. Recording of adverse reactions or adverse events: ① The investigator should 313 explain to the patients and ask them to respond truthfully to the changes in their 314 315 condition after medication and avoid induced questions; 2 While observing the efficacy, pay close attention to the observation of adverse reactions or unanticipated 316 toxic side effects, analyze the causes, make judgments, and follow up the observation 317 318 and records, and count the incidence of adverse reactions; ③ For the adverse reactions occurring during the study period, the symptoms, the degree, time of 319 appearance, duration, treatment measures, and passage should be recorded on the case 320 report form to evaluate its relevance to the test drug, and be recorded in detail by the 321 investigator, signed and dated. 322

II. Reporting of adverse reactions or adverse events: ① When adverse reactions are 323 found, the observing physician may decide whether to discontinue observation 324 according to the condition, and cases of discontinuation due to adverse reactions 325

16

should be followed up and investigated, with detailed records of treatment and results; 326 2 If serious adverse events occur in the trial, the unit undertaking the clinical study 327 328 must take immediate measures to protect the safety of the subjects and promptly inform the participating research units, and Ensure that all legal and regulatory 329 requirements for reporting procedures are met. 330

#### Data management and monitoring 331

The data management of this project was entrusted to the Data Management 332 Center of Jiangsu Famaxon Medical Technology Co. This project uses the clinical 333 334 data management platform, and the data manager constructs e-CRF according to the study protocol and case report form. 335

I. Data record 336

337 In view of the situation that most of the outpatient medical records in China's hospitals are brought by the patients themselves, to keep the first-hand data of the 338 clinical trial intact, we design this trial-specific: "study medical record". The study 339 340 medical record is the source document of the clinical trial subjects, which should be kept in the hospital. The study medical record is the medical record of the outpatient 341 subjects, and together with the inpatient medical record, it forms the medical record of 342 the subjects. 343

II. Study case record requirements 344

The investigator must write the study case record at the same time as the subject 345 is seen and treated to ensure that data are recorded in a timely, complete, accurate, and 346 truthful manner. 347

17

Any substantiated corrections made to the study medical record may only be crossed 348 out, with the corrected data noted next to it, signed and dated by the investigator, and 349 350 not erased or overwritten on the original record.

Original lab sheets for outpatient subjects are affixed to the study medical record and 351 original lab sheets for inpatient subjects are affixed to the inpatient medical record. 352 The results of laboratory tests for both outpatient and inpatient subjects must be 353 completed in the "Physical and Chemical Findings Report Form" in the study medical 354

record. 355

356 III. Review of medical records

After each subject's observation session, the investigator should submit the "study 357 medical record", "informed consent" and "patient medication record card" to the 358 359 principal investigator of the unit within 3 working days. Within one week, they should be submitted to the project leader for review and deposited in the institutional data 360 archive, and any problems found should be dealt with and recorded on time. 361

IV. Data Entry and Modification 362

Data entry and management are the responsibility of the clinical coordinator and 363 data manager, respectively. Each study center will be given a separate username and 364 password before the start of the project, and a designated person from the study center 365 will enter the raw data into the EDC via a secure network. Study center personnel will 366 be allowed to make changes to the entered data during the entry process. The 367 supervisor confirms that all data in the EDC is consistent with the original record. If 368 there are errors or omissions, a challenge form is sent to the research center personnel 369

18

to request changes to the data in the EDC. 370

371	The data management department reviews the data recorded in the EDC by standard
372	operating procedures. For queries in the data, the data manager will send a query to
373	the research center personnel in the form of a query form, requesting the designated
374	personnel of the research center to respond to the query and make the necessary
375	changes to the data. All data changes and related operations shall be recorded with a
376	trace.

V. Data Monitoring 377

378 The number of monitors and the number of visits must meet the quality control requirements of the clinical trial. Supervisors shall review each study medical record 379 and fill in the "Supervisor Review Page" one by one. 380

381 During the monitoring process, they should check the completeness of the case records and the accuracy of the case report form, verify the trial data, check the 382 compliance with the trial protocol and clinical trial management specifications, 383 384 understand the progress of the enrolled subjects, and ensure the storage, distribution, and use of the trial products. The investigator and related personnel should assist the 385 monitor during his or her visit and arrange an appropriate workspace for him or her. 386

VI. Database locking 387

388 After a blind audit and confirmation that the database created is correct, a data management audit report is written by the data manager, and the data is locked by the 389 390 principal investigator, sponsor, and statistical analyst. No further changes will be made to the locked data files. 391

19

#### DISCUSSION 392

CA is a proliferative genital perianal lesion caused by infection with the human 393 394 papilloma (HPV) virus. Its incidence is three times higher than that of genital herpes, and most patients are young people aged 18-35.[15,16] They infection of warts not 395 only has physical and psychological effects but the pathogen HPV is also 396 carcinogenic in addition to causing warty growths.[17] Evidence suggests that HPV 397 infection is closely associated with the development of cervical cancer.[18] 398 The typical CA is a small, reddish papule that gradually increases in size and has an 399 400 uneven surface, and then further proliferates into a wart-like protrusion and spreads to the periphery. The most important thing is that you can feel the pain of intercourse, 401

and occasionally the infection may be oozing, ulcerated, or bleeding. 402

403 The principles of CA treatment are to remove as many warts as possible and to reduce recurrence. Although there are several treatments for warts, there is a risk of 404 recurrence with any of them.[19] There is no definitive answer as to which method is 405 406 the best for treating warts.

In Traditional Chinese Medicine (TCM), it is mainly contact with evil toxins, and 407 damp heat, which is caused by the accumulation of damp heat toxins on the pudendal 408 skin. The TCM syndrome types of this disease are mainly divided into two types: 409 damp-heat toxin accumulation syndrome and dampness and toxicity gather in the 410 lower, while CA is mainly localized, so external treatment is often used for treatment. 411 412 The effect of drugs can penetrate the skin directly to the affected part. [20] In China, the compound external preparation mainly composed of Brucea javanica, Sophora 413

20

flavescens, Honeysuckle, Folium Isatidis, diffusa diffusa, honeydew, fructus cnidii, 414 and other traditional Chinese medicines has been used for many years. Studies have 415 416 shown that it can inhibit and kill HPV through cytotoxicity.[21,22] There are also external preparations of cantharidin, which are effective in the removal of the wart 417 body and the prevention of recurrence. However, due to the difficulty of 418 standardization and the limitations of the research methods adopted, there is a lack of 419 relevant high-quality evidence-based medical evidence. 420

421 In this trial, we will use granular formulations to minimize bias associated with the 422 use of herbs from different geographic regions, different species, and preserved under different storage conditions. In this study, it refers to clarify the superior aspects of 423 Chinese medicine in the treatment of CA and to obtain high-level evidence-based 424 425 medical evidence to provide a basis for the formation of standardized treatment protocols. 426

#### **Ethics and dissemination** 427

This trial has been ethically approved by the Ethics Committee of Shanghai 428 Yueyang Hospital of Integrative Medicine (approval number:2023-023) All 429 participants will be enrolled only after signing the informed consent form. No clinical 430 data or biological samples will be collected from those who do not participate. The 431 trial will comply with national laws, clinical practice guidelines, and the Declaration 432 of Helsinki as revised in 2013. Results will be published through meeting reports and 433 publicly available documents. 434

**Trial status** 435

436	The trial phase begins in JAN 2024 at Shanghai Yueyang Hospital for Integrative
437	Medicine and is currently being prepared for patient recruitment.

### **Contributors:** 438

- SYY drafted the manuscript. LH participated in the design of the study, and YFW 439
- coordinated the study. WXQ will generate the allocation sequence, DJG will enrol 440
- participants, and XQW and FLL will assign participants to interventions. All authors 441
- read and approved the final manuscript. 442
- Funding statement: Shanghai Municipal Health Commission Health Industry 443
- 444 Clinical Research Specialization(20224Y0056,20214Y0175), Shanghai Sailing
- Program(no.20YF1450500) 445
- Competing interests statement: None declared. 446
- 447 Patient consent Patient: recruitment has not started.
- Ethics approval: Institutional Ethics Committee of Shanghai Yueyang Integrated 448
- Medicine Hospital. 449

22

# **Figures legends** 451

# Figure 1.Flow diagram showing progress through the study 452

454	Tables								
455	Tables1. Visual analogue scale (VAS)								
456	456 Visual analogue scale								
457	No pain Worst pain imaginable								
458									
459									
460	Numerical rating scale								
461	No pain Worst imaginable pain								
	0 1 2 3 4 5 6 7 8 9 10								
462									
463	Verbal rating scale								
464	0 No pain								
465	1 Mild pain								
466	2 Moderate pain								
467	3 Severe pain								
468									
469	Tables2. VANCOUVER SCAR SCORING(VVS)								
	VANCOUVER SCAR SCORING								
	Pigmentation								
	0 Normal								
	1 Hypopigmentation or hyperpigmentation not exceeding 5% of the whole								
	2 Hyperpigmentation ranging between 5% and 30% of the whole								
	3 Hyperpigmentation not G30% of the whole								
	Vascularity								
	0 Normal								
	1 Red								
	2 Slightly dark red								
	3 Much darker red								
	Pliability								
	0 Normal								
	1 Supple								
	2 Yielding								
	3 Firm								
	4 Banding								
	5 Contracture								
	Height								
	0 Normal								
	1 Elevation of 0Y1 mm								
	2 Elevation of 1Y2 mm								
	3 Elevation of 2Y4 mm								
	4 Elevation of Q4 mm								
	Length								
	The length of the scar was measured with a medical ruler.								

# 

Adverse reaction level evaluation table					
Level 1	Safe, no adverse reactions				
Level 2	safer, minor adverse reactions, but does not affect treatment				
Level 3	There are certain safety issues, there is a certain degree of adverse reactions, but afte				
treatment can continue treatment					
Grade 4	Adverse reactions occur, resulting in the inability to continue treatment				

#### Table 4. Schedule for enrollment, intervention, and assessment

	Phase	Screening/ Enrolment	Treatment/Intervention			Follow-up		
Activity	Time points	0week	0week	1week	2week	6week	10week	14week
	Eligibility screening	•						
	Obtaining informed							
	consent	•						
	Demographic							
Scrooning/	characteristics	•						
Enrolmont	Medical history							
Linoinent	taking	•						
	Enrolment	•						
	Random allocation	•						
	Skin lesion							
	photography	•		•	•	•	•	•
	WRAWF +							
Treatment/Intervention	Photodynamic		•	•	•			
ineatiment, intervention	Placebo +							
	Photodynamic		•	•	•			
Outcomo assassment	Recurrence					•	•	$\bullet$
	Efficacy evaluation		●	•	•	•	•	$\bullet$
	VAS score		•	•	•	•	•	•
Safety assessment	Infection		•	•	•	•	•	•
	Superficial scarring		•	•	•	•	•	•

WRAWF, Wei Ren Anti-Wart Formula ; VAS, visual analogue scale

All rights reserved. No reuse allowed without permission.

25

# 477 References

- 478 1 Sarika Desai, Sally Wetten, Sarah C. Woodhall, *et al.* Genital warts and cost of care in England.
  479 Sex Transm Infect. 2011;87:464–8.
- 480 2 J. Monsonégo, J.-G. Breugelmans, S. Bouée, *et al.* [Anogenital warts incidence, medical
  481 management and costs in women consulting gynaecologists in France]. *Gynecol Obstet Fertil.*482 2007;35:107–13.
- Peter Hillemanns, J. Gabrielle Breugelmans, Friederike Gieseking, *et al.* Estimation of the
  incidence of genital warts and the cost of illness in Germany: a cross-sectional study. *BMC Infect Dis.* 2008;8:76.
- 4 Xavier Castellsagué, Catherine Cohet, Luis M. Puig-Tintoré, *et al.* Epidemiology and cost of
  487 treatment of genital warts in Spain. *Eur J Public Health*. 2009;19:106–10.
- Peiyao Zhu, Rui-Qun Qi, Yang Yang, *et al.* Clinical guideline for the diagnosis and treatment of
  cutaneous warts (2022). *J Evid Based Med.* 2022;15:284–301.
- Wang Han, Ying Xiong, Yunman Li, *et al.* Anti-arthritic effects of clematichinenoside (AR-6) on
   PI3K/Akt signaling pathway and TNF-α associated with collagen-induced arthritis. *Pharm Biol.* 2013;51:13–22.
- Yingling Sui, Deping Xu. Isolation and identification of anti-inflammatory and analgesic
  polysaccharides from Coix seed (Coix lacryma-jobi L.var. Ma-yuen (Roman.) Stapf). *Nat Prod Res.* 2022;1–10.

Yun Lu, Bing-Yuan Zhang, Zhuo-Xia Jia, *et al.* Hepatocellular carcinoma HepG2 cell apoptosis
and caspase-8 and Bcl-2 expression induced by injectable seed extract of Coix lacryma-jobi. *Hepatobiliary Pancreat Dis Int.* 2011;10:303–7.

- Guang-De Yang, Hui Zhang, Rong Lin, *et al.* Down-regulation of CD40 gene expression and
  inhibition of apoptosis with Danshensu in endothelial cells. *Basic Clin Pharmacol Toxicol*.
  2009;104:87–92.
- Ma L. Astragalus Polysaccharides Promote Wound Healing in Diabetic Rats by Upregulating
   PETN and Inhibiting the mTOR Pathway. *Comput Math Methods Med*. 2022;2022:3459102.
- Yue Y, Liu X, Pang L, *et al.* Astragalus Polysaccharides/PVA Nanofiber Membranes Containing
   Astragaloside IV-Loaded Liposomes and Their Potential Use for Wound Healing. *Evid Based Complement Alternat Med.* 2022;2022:9716271.
- Hamid M, Liu D, Abdulrahim Y, *et al.* Amelioration of CCl(4)-induced liver injury in rats by
   selenizing Astragalus polysaccharides: Role of proinflammatory cytokines, oxidative stress
   and hepatic stellate cells. *Res Vet Sci.* 2017;114:202–11.
- Abadi Aj, Mirzaei S, Mahabady Mk, *et al.* Curcumin and its derivatives in cancer therapy:
   Potentiating antitumor activity of cisplatin and reducing side effects. *Phytotherapy research :*

26

#### 512 PTR. 2022;36. doi: 10.1002/ptr.7305

- 513 14 Zhang L-L, Cai H-G, Ji Z-Zhou J, Zhang J, Yang S-J. Observation of clinical effects and analysis
- 514 of adverse reactions of carbon dioxide laser combined with photodynamic therapy for vulvar 515 acromegaly. [J] Journal of Nantong University (Medical Edition). 2022;42(01):59-61.
- 516 15 Dareng EO, Adebamowo SN, Famooto A, et al. Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. BMC Infect Dis. 2019;19:27. 517
- 518 16 Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and prevalence of 519 genital warts. BMC Infect Dis. 2013;13:39.
- 520 17 Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40:602–8.
- 521 18 Rymsza T, Ribeiro Ea, de Carvalho Lfdces, et al. Human papillomavirus detection using PCR 522 and ATR-FTIR for cervical cancer screening. Spectrochimica acta Part A, Molecular and 523 biomolecular spectroscopy. 2018;196. doi: 10.1016/j.saa.2018.02.004
- 524 19 Prayogo SA, Andrew H, Cong S, et al. Photodynamic therapy in the treatment of condyloma 525 acuminata: A systematic review of clinical trials. Int J STD AIDS. 2023;34:76-86.
- 526 20 Lei Shi, Hongwei Wang, Kun Chen, et al. Chinese guidelines on the clinical application of 527 5-aminolevulinic acid-based photodynamic therapy in dermatology (2021 edition). Photodiagnosis Photodyn Ther. 2021;35:102340. 528
- 21 Chen X, Hu X, Liu L, et al. Extracts derived from a traditional Chinese herbal formula triggers 529 530 necroptosis in ectocervical Ect1/E6E7 cells through activation of RIP1 kinase. Journal of 531 ethnopharmacology. 2019;239. doi: 10.1016/j.jep.2019.111922
- 22 Ling Ye, Jian-Fu Zhao, Yi-Ming Wang, et al. Brucea javanica oil emulsion suppresses tumor 532 growth in human cervical cancer cells through inhibition of the E6 oncogene and induction of 533 534 apoptosis. Translational cancer research. 2020;9. doi: 10.21037/tcr.2019.12.62